FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Releases Sun Pharmaceutical FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with three observations from an inspection at the Sun Pharmaceutical Medicare sterile drug manufactu...

Industry Recommendations for BsUFA 4 Reauthorization

[ Price : $8.95]

A Hyman, Phelps & McNamara CMC regulatory expert lists the initial industry recommendations for improvements to be negotiated in t...

FDA to Review Inovio BLA to Treat RRP

[ Price : $8.95]

FDA accepts for review an Inovio BLA for INO-3107 as a potential treatment for adults with recurrent respiratory papillomatosis.

Alumis Positive Data Reported for Psoriasis Drug

[ Price : $8.95]

Alumis says envudeucitinib delivered high levels of skin clearance in two pivotal Phase 3 trials in moderate-to-severe plaque psor...

Dexcom Glucose Monitor Software Correction is Class 1

[ Price : $8.95]

FDA says a recent Dexcom 9/18/2025 software correction for its Dexcom G6 and G6 Pro continuous glucose monitoring software is Clas...

FDA Town Hall on Quality Management System Regulation

[ Price : $8.95]

FDA announces a 1/14 town hall to discuss its Quality Management System Regulation (QMSR) and its effective date of 2/2/2026.

13 Potential New FAERS Drug Safety Signals

[ Price : $8.95]

FDA releases a list of 13 potential safety signals identified in drugs between 7/2025 and 9/2025.

First Cycle Review Metrics Debated at PDUFA Session

[ Price : $8.95]

In a PDUFA 8 reauthorization subgroup discussion, FDA and industry representatives trade data and evaluations of first-cycle revie...

FDA Tumult Keeps Makary Under Microscope: NYT Article

[ Price : $8.95]

The New York Times reports that ongoing turmoil at FDA has increasingly placed commissioner Marty Makary under the microscope, rai...

FDA Cites GSK Hungary Vaccine Plant

[ Price : $8.95]

FDA cites a GlaxoSmithKline biologicals manufacturing site in Hungary for significant lapses in deviation investigations and mater...